A look at Johnson & Johnson 4th-quarter sales

Tuesday - 1/22/2013, 5:45pm EST

By The Associated Press

(AP) - A look at health care giant Johnson & Johnson's fourth-quarter revenue by division and for selected products and categories:

?CONSUMER HEALTH PRODUCTS 4Q 2012 4Q 2011 Change

?U.S. Total $1.2 B $1.25 B down 3.6 percent

?International Total $2.45 B $2.42 B up 1.2 percent

?Worldwide Total $3.65 B $3.67 B down 0.4 percent

?Nonprescription drugs/nutritionals-U.S. $356 M $370 M down 3.8 percent

?

?MEDICAL DEVICES & DIAGNOSTICS 4Q 2012 4Q 2011 Change

?U.S. Total $3.24 B $2.85 B up 13.8 percent

?International Total $4.14 B $3.64 B up 13.6 percent

?Worldwide Total $7.38 B $6.49 B up 13.7 percent

?Cardiovascular Care-global $504 M $587 M down 14 percent

?Orthopedic Products-global (asterisk) $2.39 B $1.45 B up 64.3 percent

?

?PRESCRIPTION DRUGS 4Q 2012 4Q 2011 Change

?U.S. Total $3.01 B $2.89 B up 4.4 percent

?International Total $3.51 B $3.21 B up 9.5 percent

?Worldwide Total $6.53 B $6.09 B up 7.1 percent

?Remicade (immune disorders) $1.5 B $1.43 B up 5.3 percent

?Simponi (immune disorders) $181 M $119 M up 52 percent

?Stelara (psoriasis) $269 M $207 M up 30 percent

?Prezista (HIV) $353 M $316 M up 11.7 percent

?Aciphex (heartburn) $186 M $254 M down 27 percent

?Concerta (attention deficit disorder) $243 M $274 M down 11.3 percent

?Risperdal Consta (schizophrenia) $358 M $385 M down 7 percent

?Invega Sustenna (schizophrenia) $228 M $135 M up 69 percent

?Doxil (breast, ovarian cancer) $30 M $39 M down 23 percent

?Zytiga (prostate cancer) $264 M $152 M up 74 percent

?Velcade (multiple myeloma) $502 M $352 M up 43 percent

?Procrit (anemia from cancer/dialysis) $326 M $368 M down 11.4 percent

?

?TOTAL SALES 4Q 2012 4Q 2010 Change

?U.S. $7.46 B $6.99 B up 6.8 percent

?International $10.1 B $9.27 B up 8.9 percent

?Worldwide Total $17.56 B $16.26 B up 8 percent

(asterisk) Orthopedic sales jumped mainly due to Synthes acquisition.

____

Source: Johnson & Johnson


(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)